Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis

Oncogene volume 24, pages 4421–4432 (2005)Cite this article

Abstract

Altered expression of apoptosis-regulating genes plays an important role in the aggressive growth behavior and chemoresistance of pancreatic ductal adenocarcinoma. In the present study, the hypoxia-inducible proapoptotic gene, BNIP3, was analysed in terms of expression, effect on patient survival and chemo-responsiveness in pancreatic cancer cell lines. cDNA microarray, real-time light cycler® quantitative polymerase chain reaction, laser-capture microdissection and immunohistochemistry analyses were used to evaluate BNIP3 expression in normal and diseased pancreatic specimens. Modulation of BNIP3 expression was achieved using specific siRNA molecules. The effect of chemotherapeutic agents on pancreatic cancer cells was assessed utilizing 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide assays. BNIP3 mRNA levels were 3.0- and 6.3-fold lower in chronic pancreatitis and pancreatic cancer compared to the normal pancreas, respectively. Microdissection analysis confirmed the reduction of BNIP3 expression in pancreatic cancer cells compared to normal duct cells. By immunohistochemistry, BNIP3 was predominantly expressed in the acinar cells of the normal and diseased pancreas. Interestingly, while BNIP3 was undetectable in the cancer cells of 59% of the cases, 75–100% of PanIN2/3 lesions displayed BNIP3 immunoreactivity. Loss of BNIP3 expression correlated with poorer survival of patients (8 vs 14 months for BNIP3 negative vs positive tumors). Hypoxia induced BNIP3 expression in four out of eight pancreatic cancer cell lines, while it was absent under normoxic and hypoxic conditions in the remaining four. Downregulation of BNIP3 resulted in increased resistance to 5-fluoro-uracil and gemcitabine. In conclusion, loss of BNIP3 expression occurs late in pancreatic cancer, contributes to resistance to chemotherapy and correlates with a worsened prognosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Adams JM and Cory S . (1998). Science, 281, 1322–1326.

  • Bacon AL and Harris AL . (2004). Ann. Med., 36, 530–539.

  • Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET and Giavazzi R . (2004). Mol. Cancer Ther., 3, 111–121.

  • Bold RJ, Chandra J and McConkey DJ . (1999). Ann. Surg. Oncol., 6, 279–285.

  • Brandt R, Grutzmann R, Bauer A, Jesnowski R, Ringel J, Lohr M, Pilarsky C and Hoheisel JD . (2004). Pancreatology, 4, 587–597.

  • Bruick RK . (2000). Proc. Natl. Acad. Sci. USA, 97, 9082–9087.

  • Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD . (1997). J. Clin. Oncol., 15, 2403–2413.

  • Chen G, Cizeau J, Vande Velde C, Park JH, Bozek G, Bolton J, Shi L, Dubik D and Greenberg A . (1999). J. Biol. Chem., 274, 7–10.

  • Chen G, Ray R, Dubik D, Shi L, Cizeau J, Bleackley RC, Saxena S, Gietz RD and Greenberg AH . (1997). J. Exp. Med., 186, 1975–1983.

  • Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A and Lemoine NR . (2002). Oncogene, 21, 4587–4594.

  • Crown J, Casper ES, Botet J, Murray P and Kelsen DP . (1991). J. Clin. Oncol., 9, 1682–1686.

  • Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK and Barlow JF . (1990). Cancer, 65, 2207–2212.

  • Daido S, Kanzawa T, Yamamoto A, Takeuchi H, Kondo Y and Kondo S . (2004). Cancer Res., 64, 4286–4293.

  • de Angelis PM, Fjell B, Kravik KL, Haug T, Tunheim SH, Reichelt W, Beigi M, Clausen OP, Galteland E and Stokke T . (2004). Int. J. Oncol., 24, 1279–1288.

  • Friess H, Buchler MW, Mueller C and Malfertheiner P . (1998a). Gastroenterology, 115, 1018–1022.

  • Friess H, Ding J, Kleeff J, Fenkell L, Rosinski JA, Guweidhi A, Reidhaar-Olson JF, Korc M, Hammer J and Buchler MW . (2003). Cell Mol. Life Sci., 60, 1180–1199.

  • Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM and Buchler MW . (1998b). Gut, 43, 414–421.

  • Giatromanolaki A, Koukourakis MI, Sowter HM, Sivridis E, Gibson S, Gatter KC and Harris AL . (2004). Clin. Cancer Res., 10, 5566–5571.

  • Graber HU, Friess H, Zimmermann A, Korc M, Adler G, Schmid R and Buchler MW . (1999). J. Gastrointest. Surg., 3, 74–80; discussion 81.

  • Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ . (1996). Nature, 379, 88–91.

  • Graham RM, Frazier DP, Thompson JW, Haliko S, Li H, Wasserlauf BJ, Spiga MG, Bishopric NH and Webster KA . (2004). J. Exp. Biol., 207, 3189–3200.

  • Greijer AE and van der Wall E . (2004). J. Clin. Pathol., 57, 1009–1014.

  • Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, Giese T, Korc M, Buchler MW and Friess H . (2004). Oncogene, 23, 71–81.

  • Hanahan D and Weinberg RA . (2000). Cell, 100, 57–70.

  • Harris AL . (2002). Nat. Rev. Cancer, 2, 38–47.

  • Imazu T, Shimizu S, Tagami S, Matsushima M, Nakamura Y, Miki T, Okuyama A and Tsujimoto Y . (1999). Oncogene, 18, 4523–4529.

  • Kennedy AS, Harrison GH, Mansfield CM, Zhou XJ, Xu JF and Balcer-Kubiczek EK . (2000). Int. J. Cancer, 90, 175–185.

  • Kerr JF, Winterford CM and Harmon BV . (1994). Cancer, 73, 2013–2026.

  • Ketterer K, Rao S, Friess H, Weiss J, Buchler MW and Korc M . (2003). Clin. Cancer Res., 9, 5127–5136.

  • Kleeff J, Friess H, Simon P, Susmallian S, Buchler P, Zimmermann A, Buchler MW and Korc M . (1999a). Digest. Dis. Sci., 44, 1793–1802.

  • Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D and Korc M . (1999b). Oncogene, 18, 5363–5372.

  • Kleeff J, Maruyama H, Friess H, Buchler MW, Falb D and Korc M . (1999c). Biochem. Biophys. Res. Commun., 255, 268–273.

  • Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A and Wils J . (1999). Ann. Surg., 230, 776–782; discussion 782–784.

  • Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, Bastidas AJ and Vierra M . (2000). Int. J. Radiat. Oncol. Biol. Phys., 48, 919–922.

  • Korsmeyer SJ . (1992). Blood, 80, 879–886.

  • Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K, Kirshenbaum LA and Gibson SB . (2003). Oncogene, 22, 4734–4744.

  • Lamy L, Ticchioni M, Rouquette-Jazdanian AK, Samson M, Deckert M, Greenberg AH and Bernard A . (2003). J. Biol. Chem., 278, 23915–23921.

  • Monti P, Marchesi F, Reni M, Mercalli A, Sordi V, Zerbi A, Balzano G, Di Carlo V, Allavena P and Piemonti L . (2004). Virchows Arch., 445, 236–247.

  • Moskaluk CA, Hruban RH and Kern SE . (1997). Cancer Res., 57, 2140–2143.

  • Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ and Buchler MW . (2004). N. Engl. J. Med., 350, 1200–1210.

  • Okami J, Simeone DM and Logsdon CD . (2004). Cancer Res., 64, 5338–5346.

  • Ray R, Chen G, Vande Velde C, Cizeau J, Park JH, Reed JC, Gietz RD and Greenberg AH . (2000). J. Biol. Chem., 275, 1439–1448.

  • Reynolds TY, Rockwell S and Glazer PM . (1996). Cancer Res., 56, 5754–5757.

  • Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S and Trede M . (2003). World J. Surg., 27, 324–329.

  • Schmaltz C, Hardenbergh PH, Wells A and Fisher DE . (1998). Mol. Cell. Biol., 18, 2845–2854.

  • Schmidt-Kastner R, Aguirre-Chen C, Kietzmann T, Saul I, Busto R and Ginsberg MD . (2004). Brain Res., 1001, 133–142.

  • Shi X, Liu S, Kleeff J, Friess H and Buchler MW . (2002). Oncology, 62, 354–362.

  • Sowter HM, Ferguson M, Pym C, Watson P, Fox SB, Han C and Harris AL . (2003). J. Pathol., 201, 573–580.

  • Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH and Harris AL . (2001). Cancer Res., 61, 6669–6673.

  • Takaori K, Hruban RH, Maitra A and Tanigawa N . (2004). Pancreas, 28, 257–262.

  • Tenedini E, Fagioli ME, Vianelli N, Tazzari PL, Ricci F, Tagliafico E, Ricci P, Gugliotta L, Martinelli G, Tura S, Baccarani M, Ferrari S and Catani L . (2004). Blood, 104, 3126–3135.

  • Tracey L, Spiteri I, Ortiz P, Lawler M, Piris MA and Villuendas R . (2004). J. Interferon Cytokine Res., 24, 185–195.

  • Vande Velde C, Cizeau J, Dubik D, Alimonti J, Brown T, Israels S, Hakem R and Greenberg AH . (2000). Mol. Cell. Biol., 20, 5454–5468.

  • Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H and Buchler MW . (2004). Br. J. Surg., 91, 586–594.

  • Warshaw AL and Fernandez-del Castillo C . (1992). N. Engl. J. Med., 326, 455–465.

  • White E . (1996). Genes Dev., 10, 1–15.

  • Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE and Hruban RH . (2000). Cancer Res., 60, 2002–2006.

  • Xu ZW, Friess H, Buchler MW and Solioz M . (2002). Cancer Chemother. Pharmacol., 49, 504–510.

  • Yasuda M, Theodorakis P, Subramanian T and Chinnadurai G . (1998). J. Biol. Chem., 273, 12415–12421.

  • Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB and Abrams RA . (1997). Ann. Surg., 226, 248–257; discussion 257–260.

  • Yook YH, Kang KH, Maeng O, Kim TR, Lee JO, Kang KI, Kim YS, Paik SG and Lee H . (2004). Biochem. Biophys. Res. Commun., 321, 298–305.

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery, University of Heidelberg, Im Neuenheimer Feld 110, Heidelberg, 69120, Germany

    Mert Erkan, Jörg Kleeff, Knut Ketterer, Markus W Büchler, Nathalla A Giese & Helmut Friess

  2. Institute of Pathology, University of Heidelberg, Heidelberg, 69120, Germany

    Irene Esposito

  3. Institute of Immunology, University of Heidelberg, Heidelberg, 69120, Germany

    Thomas Giese

Authors
  1. Mert Erkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jörg Kleeff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irene Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Giese
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Knut Ketterer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Markus W Büchler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nathalla A Giese
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Helmut Friess
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erkan, M., Kleeff, J., Esposito, I. et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24, 4421–4432 (2005). https://doi.org/10.1038/sj.onc.1208642

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208642

Keywords

This article is cited by

Search

Advanced search

Quick links